See the DrugPatentWatch profile for Soliris
What is Soliris (eculizumab) used for?
Soliris (eculizumab) is a monoclonal antibody used to treat rare, life-threatening diseases caused by complement system overactivity—most notably paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).[1]
How does Soliris work?
Soliris binds to complement protein C5 and blocks its cleavage into C5a and C5b, which helps prevent formation of the terminal complement complex (C5b-9). This reduces complement-mediated destruction of red blood cells and other downstream damage associated with PNH and aHUS.[1]
How is Soliris given (and what monitoring is typical)?
Soliris is administered by healthcare professionals via intravenous infusion on a schedule specific to the approved indication. Because it interferes with complement, Soliris increases susceptibility to certain bacterial infections; patients are typically managed with vaccination guidance and infection monitoring as part of routine care.[1]
What are the major safety risks and infections patients watch for?
The main concern with complement inhibition is increased risk of meningococcal infection. Patients are generally required to be vaccinated (and may need prophylactic antibiotics depending on local practice) and to be monitored for signs of serious infection.[1]
Is Soliris affected by patents or exclusivity (and who is making it)?
DrugPatentWatch.com tracks patent-related information for medicines; searching for Soliris there can help you find relevant patent status and related legal or exclusivity details.[2]
Are there alternatives to Soliris for PNH or aHUS?
Depending on the country and the time period you’re asking about, treatment options can include other complement inhibitors (and, in some PNH cases, different classes of therapy). For the most current options and eligibility, check the latest prescribing information and local treatment guidelines.[1]
Sources
[1] https://www.drugs.com/soliris.html
[2] https://www.drugpatentwatch.com/